Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

Beyond Air Q2 2026 Results: Net Loss of $7.82M, Loss Narrows

Beyond Air, Inc. reported a net loss of $15.8 million for the six months ended September 30, 2026, compared to $15.6 million in the prior year period. While revenues increased to $4.1 million from $3.6 million, the company faced significant interest expenses and a loss on debt extinguishment, ending the period with $5.4 million in cash and cash equivalents.

Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Revenue2.31.8
Gross profit0.2-0.3
Profit before tax-8.2-8.3
Net income-7.8-7.9
EPS (diluted, $ a share)$-3.76$-24.98

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+27.8%
Gross margin8.5%
Operating margin-257.1%
Source

10-Q filed with the SEC, NASDAQ: XAIR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Beyond Air, Inc.: key numbers

Share price
$2.02Close, Nov 16
Market cap
$3.37M
Shares outstanding
1.67MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Beyond Air, Inc.

All →
5:01 PM ET 8-K
Financial Results

Beyond Air Financial Results

Beyond Air reported record quarterly revenue of $2.3 million for the period ended September 30, 2026, representing 28% year-over-year growth. The company reaffirmed its revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 while awaiting FDA approval for its second-generation LungFit PH system.

Term
Q2 2027

“Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval.”

Robert Goodman, Chief Executive Officer of Beyond Air

“We remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system.”

Robert Goodman, Chief Executive Officer of Beyond Air
8:41 AM ET 8-K
Business Update

Beyond Air Business Update

Beyond Air preannounced preliminary unaudited revenue of $2.3 million for the quarter ended September 30, 2026, representing 30% sequential growth. The company also reaffirmed its full-year revenue guidance for 2026 and 2027 while noting its second-generation LungFit PH system remains under FDA review.

8:25 PM ET Form 4
Insider Buying

Beyond Air Insider Yi-Chien Lin Buys $43.1K of Stock

Yi-Chien Lin bought 15,393 shares of Beyond Air, Inc. at $2.80 a share, worth $43.1K in total on Oct 1, 2026. Shares held after the trade: 145,393 (+11.8%).

Value
$43.1K
Shares
15,393
Price
$2.80
Holding change
+11.8%
Trade date
Oct 1, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.